Lupin inks licensing pact with Alvion Pharmaceuticals to market drugs in Southeast Asia

Lupin inks licensing pact with Alvion Pharmaceuticals to market drugs in Southeast Asia

AgenciesUpdated: Tuesday, April 05, 2022, 05:32 PM IST
article-image
Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region. / Representative Image |

Drug maker Lupin on Tuesday said it has inked a licensing pact with Alvion Pharmaceuticals to commercialise medicines for cardiometabolic diseases in Southeast Asia.

The Mumbai-based company said it is committed to providing affordable treatment options to healthcare providers and patients.

By commercialising cardiometabolic drugs in Southeast Asia, Lupin will play a significant role in improving the quality of healthcare and access to medicines, it added.

''Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system,'' Lupin Regional Head Southeast Asia Gabriel Georgy said in a statement.

Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region, he added.

''Being a leader in value-added medicines, Alvion shall support Lupin's activities aiming to position both companies at the forefront for both molecules,'' Alvion CEO John Bouros said.

(With inputs from PTI)

RECENT STORIES

EPFO Changes PF Withdrawal Rules, Govt’s Festive Surprise To Benefit Millions — Here's What’s...

EPFO Changes PF Withdrawal Rules, Govt’s Festive Surprise To Benefit Millions — Here's What’s...

Indian Markets Open Higher Amid Global Concerns, Sensex & Nifty Gain On Metal Boost

Indian Markets Open Higher Amid Global Concerns, Sensex & Nifty Gain On Metal Boost

Anil Ambani’s Reliance Group Shares Fall Up To 10% After ED Arrests Senior Executive In Fake Bank...

Anil Ambani’s Reliance Group Shares Fall Up To 10% After ED Arrests Senior Executive In Fake Bank...

EPFO Allows 100% Withdrawal Under Liberalised Rules For Over 7 Crore Subscribers

EPFO Allows 100% Withdrawal Under Liberalised Rules For Over 7 Crore Subscribers

SEBI Chief Urges Mutual Fund Trustees To Strengthen Early Warning Systems

SEBI Chief Urges Mutual Fund Trustees To Strengthen Early Warning Systems